Serina Therapeutics Announces President and CEO will Deliver Invited Talk on SER-214 at the CNS Diseases World Summit in Boston

Huntsville, AL, September 12th, 2016

Serina Therapeutics, Inc., a pharmaceutical research and development company that has developed a proprietary, patented polymer technology platform for drug development based upon polyoxazoline (POZ™), announced today that the Dr. Randall Moreadith, President and CEO, will deliver an invited talk on September 12th at the annual CNS Diseases World Summit in Boston, MA.

“I am delighted to be invited to speak at such a prestigious meeting on new approaches for CNS diseases. The speakers at this meeting will address many of the pressing issues in development and treatment of these debilitating diseases, and I am pleased to be able to present an update on the SER-214 Phase I clinical trial in Parkinson’s disease patients,” said Dr. Moreadith.

SER-214, a once-per-week subcutaneous administration of rotigotine delivered in a standard insulin syringe, is currently being studied in a Phase I program in patients suffering from Parkinson’s disease. “SER-214 is designed to deliver therapeutic levels of rotigotine over the entire dosing period following a single weekly injection. This approach provides continuous dopaminergic tone and prevents the phasic peak and trough of many oral dopamine-like drugs that lead to the disabling dyskinesia eventually experienced by all patients.” said Dr. Moreadith. “We believe that SER-214 will not only become an important therapeutic in the treatment of Parkinson’s disease allowing patients to enjoy a better quality of life, but will also demonstrate the power of the POZ platform in addressing unmet medical need through customized drug delivery.”

In addition to advancing its pipeline programs in pain, oncology, refractory seizures and inflammatory diseases, Serina is currently collaborating with leading pharmaceutical companies to further unlock the promise of the POZ platform and is actively seeking new partnerships.

About Serina

Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL that has developed novel polymer therapeutics based on its proprietary polyoxazoline (POZ™) technology platforms. The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled thirteen approved polyethylene glycol (PEG) products
for various pharmaceutical partners. POZ technology provides strong differential characteristics that may demonstrate improved clinical benefits versus PEG and other polymer-based technologies. Besides developing its own pipeline of pharmaceutical products for Parkinson’s disease and cancer, Serina has partnered its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs.

For more information on Serina Therapeutics, please visit www.serinatherapeutics.com.